Policy
FDA Approves Lilly's Olumiant for Adolescents 12 and Older With Severe Alopecia Areata
In the BRAVE-AA-PEDS trial, 42% of adolescents on the 4-mg dose reached at least 80% scalp hair coverage at week 36, against 5% on placebo.
ME
By Marcus Elrod
Sep 26, 2026 · 5 min read
The Food and Drug Administration has approved Eli Lilly's Olumiant, or baricitinib, for pediatric patients aged 12 and older with severe alopecia areata, the company said in an announcement issued Friday at 5:11 p.m. Eastern.
Discussion (0)
Sign in to join the discussion.
Loading comments…
ME
Marcus Elrod
Marcus tracks positioning, flows and rates. He writes CI's weekly market internals column.
Marcus Elrod writes for Corporate Insider Inc.